Efficacy Evaluation Analysis Service
Two essential points of the biological effect of RDC (Radionuclide Drug Conjugate), termed potency, are affinity and efficacy. Efficacy evaluation is the ultimate study before clinical research.
Rdcthera, with an excellent RDC analysis platform, has provided in vivo efficacy evaluation analysis service for years for global research institutions and companies with an in-depth interpretation of the experimental results.
Overview of Efficacy Evaluation
RDC, as a class of highly potent biopharmaceutical agents for oncological and hematological disorder treatments, is widely studied and some of them are approved. One important pharmacological parameter of the RDC is the in vivo efficacy, which directly demonstrates the potency of RDC and can influence the clinical study.
The PK (Pharmacokinetics) and PD (Pharmacodynamics) are two important parts of in vivo efficacy evaluation. Notably, PK is the study of how the organism affects the drug, while PD is the study of how a drug affects an organism, together influencing dosing, benefit, and adverse effects.
- PK
Pharmacokinetics properties, affected by the administration method and dose, which may change the absorption rate, showing the movement of drugs through the body (including adsorption, distribution, excretion, and metabolism), can demonstrate three properties of RDC products.
- How the body reacts to the specific RDC, through the absorption and distribution process;
- Metabolic changes of RDC in the body;
- The influences and excretion routes of the metabolites of the RDC.
- PD
Pharmacodynamics is the study of the biochemical and physiologic effects of RDC, particularly emphasizing dose-response relationships, which are the relationships between drug concentration and effect. The intricate influences of RDC can be divided into two parts, including the expected direct effects and the undesirable effects.
Our Service
As a conjugated compound, efficacy evaluation of RDC is much more complicated, because of the combined function between the radionuclide and the targeting molecule. Rdcthera can provide efficacy evaluation with a full understanding of the intricate efficacy of RDC in vivo.
- Mammal Models in Efficacy Evaluation Analysis
Rdcthera can provide professional efficacy evaluation with well-established tumor animal models, with duplicated experiments to guarantee the accuracy of our data. All of our animals, feed in a clean and comfortable environment, are utilized to perform experiments under Institutional Animal Care and Use Committee (IACUC) approved protocols.
- Syngeneic Tumor Mouse Model
- Human Xenograft Mouse Model
|
|
|
|
- PK Analysis Service
Rdcthera can provide professional pharmacokinetic assays and mathematical pharmacokinetic models to predict the absorption, distribution, metabolism, and excretion of your RDC product.
- PD Analysis Service
Rdcthera offer pharmacodynamic services for anticancer RDC development, including organ-and animal- based studies containing different cancer models to evaluate the efficacy of RDC in vivo.
Our data helps companies and institutions unravel the function of their RDC by providing quantitative information about how RDC influence tumor in vivo. Using our platform, you can quickly and economically test the ability of your RDC product to damage tumor cells accurately with large sample sizes of animal models in a short time to accelerate your RDC development process.
Project Workflow
Why Choose Us
Rdcthera is professional at in vivo analysis and can offer premium quality efficacy evaluation analysis service for your RDC project and can provide flexible services based on your requirements. Please contact us for more information.
For research use only. Not intended for any clinical use.
Related Service
